Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 24.99
PIP's Cash to Debt is ranked higher than
70% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. PIP: 24.99 )
PIP' s 10-Year Cash to Debt Range
Min: 0.33   Max: No Debt
Current: 24.99

Equity to Asset 0.83
PIP's Equity to Asset is ranked higher than
83% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PIP: 0.83 )
PIP' s 10-Year Equity to Asset Range
Min: -0.3   Max: 0.83
Current: 0.83

-0.3
0.83
Interest Coverage No Debt
PIP's Interest Coverage is ranked higher than
61% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PIP: No Debt )
PIP' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 3.20
M-Score: -4.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -100.02
PIP's Operating margin (%) is ranked higher than
71% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. PIP: -100.02 )
PIP' s 10-Year Operating margin (%) Range
Min: -873.96   Max: 55.46
Current: -100.02

-873.96
55.46
Net-margin (%) -97.68
PIP's Net-margin (%) is ranked higher than
71% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. PIP: -97.68 )
PIP' s 10-Year Net-margin (%) Range
Min: -909.98   Max: 47.27
Current: -97.68

-909.98
47.27
ROE (%) -79.12
PIP's ROE (%) is ranked higher than
59% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. PIP: -79.12 )
PIP' s 10-Year ROE (%) Range
Min: -453.67   Max: -27.07
Current: -79.12

-453.67
-27.07
ROA (%) -54.06
PIP's ROA (%) is ranked higher than
60% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. PIP: -54.06 )
PIP' s 10-Year ROA (%) Range
Min: -111.46   Max: -15.19
Current: -54.06

-111.46
-15.19
ROC (Joel Greenblatt) (%) -2766.56
PIP's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. PIP: -2766.56 )
PIP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2862.64   Max: -186.46
Current: -2766.56

-2862.64
-186.46
Revenue Growth (3Y)(%) -29.30
PIP's Revenue Growth (3Y)(%) is ranked higher than
63% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. PIP: -29.30 )
PIP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -30.1   Max: 173.4
Current: -29.3

-30.1
173.4
EBITDA Growth (3Y)(%) 34.40
PIP's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. PIP: 34.40 )
PIP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -66.7   Max: 34.4
Current: 34.4

-66.7
34.4
EPS Growth (3Y)(%) 28.60
PIP's EPS Growth (3Y)(%) is ranked higher than
91% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. PIP: 28.60 )
PIP' s 10-Year EPS Growth (3Y)(%) Range
Min: -64.7   Max: 28.6
Current: 28.6

-64.7
28.6
» PIP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PIP Guru Trades in Q1 2014

Jim Simons 21,700 sh (-46.42%)
» More
Q2 2014

PIP Guru Trades in Q2 2014

Jim Simons Sold Out
» More
Q3 2014

PIP Guru Trades in Q3 2014

Louis Moore Bacon 50,000 sh (New)
» More
Q4 2014

PIP Guru Trades in Q4 2014

Louis Moore Bacon 50,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PIP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.40
PIP's P/B is ranked higher than
66% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. PIP: 5.40 )
PIP' s 10-Year P/B Range
Min: 1.3   Max: 31.64
Current: 5.4

1.3
31.64
P/S 9.15
PIP's P/S is ranked higher than
75% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. PIP: 9.15 )
PIP' s 10-Year P/S Range
Min: 0.44   Max: 103.75
Current: 9.15

0.44
103.75
Current Ratio 7.46
PIP's Current Ratio is ranked higher than
83% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. PIP: 7.46 )
PIP' s 10-Year Current Ratio Range
Min: 0.53   Max: 170.53
Current: 7.46

0.53
170.53
Quick Ratio 7.46
PIP's Quick Ratio is ranked higher than
83% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. PIP: 7.46 )
PIP' s 10-Year Quick Ratio Range
Min: 0.53   Max: 170.53
Current: 7.46

0.53
170.53
Days Sales Outstanding 3.98
PIP's Days Sales Outstanding is ranked higher than
99% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. PIP: 3.98 )
PIP' s 10-Year Days Sales Outstanding Range
Min: 3.98   Max: 319.57
Current: 3.98

3.98
319.57

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.00
PIP's Price/Net Cash is ranked higher than
84% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. PIP: 7.00 )
PIP' s 10-Year Price/Net Cash Range
Min: 3.26   Max: 186
Current: 7

3.26
186
Price/Net Current Asset Value 6.80
PIP's Price/Net Current Asset Value is ranked higher than
82% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. PIP: 6.80 )
PIP' s 10-Year Price/Net Current Asset Value Range
Min: 1.48   Max: 22.26
Current: 6.8

1.48
22.26
Price/Tangible Book 6.50
PIP's Price/Tangible Book is ranked higher than
70% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. PIP: 6.50 )
PIP' s 10-Year Price/Tangible Book Range
Min: 1.48   Max: 37
Current: 6.5

1.48
37
Price/Median PS Value 2.80
PIP's Price/Median PS Value is ranked higher than
68% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. PIP: 2.80 )
PIP' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 3.12
Current: 2.8

0.24
3.12
Earnings Yield (Greenblatt) -11.60
PIP's Earnings Yield (Greenblatt) is ranked higher than
52% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. PIP: -11.60 )
PIP' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11.8   Max: 0.9
Current: -11.6

-11.8
0.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
PharmAthene Inc was incorporated under the laws of the State of Delaware on April 25, 2005. It is a biodefense company, which is engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. Its biodefense portfolio includes the product candidates namely SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine; Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and; rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides. The Company's customers are the U.S. Department of Defense (the DoD), the National Institute of Allergy and Infectious Diseases ('NIAID), and the National Institute of Health (NIH). Its competitors include Emergent BioSolutions, Inc., Green Cross, Panacea Biotec Ltd., and PaxVax, among others. The Company is subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its various activities.
» More Articles for PIP

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
PharmAthene Inc (PIP) CEO Eric I Richman buys 10,000 Shares Jun 21 2010 
Guru Activities for Today’s Price % Losers: PharmAthene Inc. , Authentidate Holding Corp., Kroger Dec 08 2009 

More From Other Websites
PharmAthene Receives $5.8 Million Payment From BARDA Apr 13 2015
PHARMATHENE, INC Financials Mar 18 2015
PharmAthene Reports Year-End 2014 Financial And Operational Results; Announces Plan To Realign... Mar 15 2015
PHARMATHENE, INC Files SEC form 10-K, Annual Report Mar 11 2015
PHARMATHENE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Mar 09 2015
PharmAthene reports 4Q loss Mar 09 2015
PharmAthene Reports Year-End 2014 Financial And Operational Results; Announces Plan To Realign... Mar 09 2015
Eli Lilly CEO: Big pharma needs to change its strategy Mar 04 2015
PharmAthene rPA Antigen Formulated With DepoVax™ Demonstrates Promise As Single Unit Dose Anthrax... Feb 02 2015
PharmAthene rPA Antigen Formulated With DepoVax™ Demonstrates Promise As Single Unit Dose Anthrax... Feb 02 2015
Siga Must Pay Total of $194 Million in Smallpox-Drug Case Jan 15 2015
PharmAthene Awarded $195 Million Plus Post-Judgment Interest By Delaware Court Of Chancery Jan 15 2015
PHARMATHENE, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 12 2015
Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To... Jan 07 2015
Delaware court orders Siga to pay PharmAthene $113 mln Jan 07 2015
Amgen announces treatment to compete with Juno, other Seattle biotechs as it exits region Jan 05 2015
PharmAthene Fulfills Valortim® IDIQ Contract Nov 20 2014
PharmAthene Fulfills Valortim® IDIQ Contract Nov 20 2014
PHARMATHENE, INC Files SEC form 10-Q, Quarterly Report Nov 06 2014
PHARMATHENE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK